NCT06110182

Brief Summary

This is a multicenter retrospective study (Reims and Nancy), with data collection over 12 years from 01/01/2010 to 12/31/2022 Patients included are children diagnosed with acute lymphoblastic leukemia between 2010 and 2021 in the 2 centers. Patients will be categorized into 3 groups:

  • No nutritional support
  • Support by enteral nutrition
  • Parenteral nutrition support Their nutritional status will be assessed at the end of induction, at 6 months and then at 12 months from diagnosis. The main objective of this study is therefore to compare the nutritional status of children with acute lymphoblastic leukemia depending on whether they received enteral or parenteral nutritional support during their treatment. The secondary objective is to evaluate the occurrence of complications during treatment according to the nutritional support received.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2023

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

October 26, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 31, 2023

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2025

Completed
Last Updated

October 31, 2023

Status Verified

October 1, 2023

Enrollment Period

1.5 years

First QC Date

October 26, 2023

Last Update Submit

October 26, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Z-score

    Compare the improvement in Z-score between the date of diagnosis and 6 months from diagnosis in children using parenteral nutrition and those using enteral nutrition during treatment of their acute lymphoblastic leukemia

    6 months

Secondary Outcomes (3)

  • BMI

    6 months

  • albumin

    6 months

  • complications

    1 year

Study Arms (2)

enteral nutrition

children who received enteral nutritional support during treatment

Dietary Supplement: enteral or parenteral nutritional support

parenteral nutrition

children who received parenteral nutritional support during treatment

Dietary Supplement: enteral or parenteral nutritional support

Interventions

Parents will be classified based on whether they received enteral or parenteral nutritional support during treatment.

enteral nutritionparenteral nutrition

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

children diagnosed with acute lymphoblastic leukemia between 2010 and 2021 in Nancy and Reims

You may qualify if:

  • Children between 1 and 18 years old diagnosed with Medium risk/ High Risk B acute lymphoblastic leukemia or Standard/ High Risk T acute lymphoblastic leukemia between 2010 and 2021 in Nancy and Reims.

You may not qualify if:

  • Patients less than 1 year old
  • leukémia with philadelphia chromosome
  • standard risk B acute lymphoblastic leukemia
  • bone marrow transplant during treatment
  • death during the year following diagnosis
  • refusal of the patient (parents) to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHRU Nancy

Vandœuvre-lès-Nancy, 54500, France

Location

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Hélène DEUTSCH

Study Record Dates

First Submitted

October 26, 2023

First Posted

October 31, 2023

Study Start

October 1, 2023

Primary Completion

April 1, 2025

Study Completion

May 1, 2025

Last Updated

October 31, 2023

Record last verified: 2023-10

Locations